[1]Schwimmer JB, Deutsch R, Kahen T, et al.Prevalence offatty liver in children and adolescents[J].Pediatrics, 2006, 118 (4) :1388-1393.
|
[2]Fan JG, Zhu J, Li XJ, et al.Prevalence of risk factors for fat-ty liver in a general population of Shanghai[J].China J Hep-atol, 2005, 43 (3) :508-514.
|
[3]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志, 2006, 14 (3) :161-163.
|
[4] 中华医学会糖尿病分会.2007年中国2型糖尿病防治指南[J].中华内分泌代谢杂志, 2008, 24 (2) :增录1-附录26.
|
[5]Hashizume H, Sato K, Takagi H, et al.Primary liver cancerwith nonalcoholic steatohepatitis[J].Eur J GastroenterolHepatol, 2007, 19 (10) :827-834.
|
[6]Petta S, CraxìA.Hepatocellular carcinoma and non-alcohol-ic fatty liver disease:from a clinical to a molecular association[J].Curr Pharm Des, 2010, 16 (6) :741-52.
|
[7]钟黄, 李良平.非酒精性脂肪肝、隐源性肝硬化与原发性肝癌发生的关系[J].国际消化病杂志, 2009, 29 (6) :402-405.
|
[8]Alkhouri N, Tamimi TA, Yerian L, et al.The inflamed liverand atherosclerosis:a link between histologic severity ofnonalcoholic fatty liver disease and increased cardiovascularrisk[J].Dig Dis Sci, 2010, 55 (9) :2644-2650.
|
[9]Adams LA, Waters OR, Knuiman MW, et al.NAFLD as arisk factor for the development of diabetes and the metabolicsyndrome:an eleven-year follow-up study[J].Am JGastroenterol, 2009, 104 (4) :861-867.
|
[10]Adams LA, Harmsen S, St Sauver JL, et al.Nonalcoholicfatty liver disease increases risk of death among patientswith diabetes:a community-based cohort study[J].Am JGastroenterol, 2010, 105 (7) :1567-1573.
|
[11]Lizardi-Cervera J, Aguilar-Zapata D.Nonalcoholic fatty liv-er disease and its association with cardiovascular disease[J].Ann Hepatol, 2009, 8 (Suppl 1) :S40-S43.
|
[12]Bantel H, Lugering A, Heidemann J, et al.Detection of ap-optotic caspase activation in sera from patients with chronicHCV infection is associated with fibrotic liver injury[J].Hep-atology, 2004, 40 (5) :1078-1087.
|
[13]Wieckowska A, Zein NN, Yerian LM, et al.In vivo assess-ment of liver cell apoptosis as a novel biomarker of diseaseseverity in nonalcoholic fatty liver disease[J].Hepatology, 2006, 44 (1) :27-31.
|
[14]Feldstein AE, Wieckowska A, Lopez AR, et al.Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalco-holic steatohepatitis:a multicenter validation study[J].Hepatology, 2009, 50 (4) :1072-1078.
|
[15]Canbakan B, Senturk H, Canbakan M, et al.Is alanine amin-otransferase level a surrogate biomarker of hepatic apoptosisin nonalcoholic fatty liver disease?[J].Biomark Med, 2010, 4 (2) :205-214.
|
[16]Iubitskaia NS, Antoniuk MV, Veremchuk LV, et al.Role oftumor necrosis factor in the development of metabolic syn-drome[J].Ter Arkh, 2009, 81 (11) :59-63.
|
[17]Riquelme A, Arrese M, Soza A, et al.Non-alcoholic fattyliver disease and its association with obesity, insulin resist-ance and increased serum levels of C-reactive protein inHispanics[J].Liver Int, 2009, 29 (1) :82-88.
|
[18]Lemoine M, Ratziu V, Kim M, et al.Serum adipokine levelspredictive of liver injury in non-alcoholic fatty liver disease[J].Liver Int, 2009, 29 (9) :1431-1438.
|
[19]Manco M, Marcellini M, DeVito R, et al.Metabolic syndromeand liver histology in paediatric non-alcoholic steatohepatitis[J].International Journal of obesity, 2008, 32 (2) :381-387.
|
[20]Valva P, De Matteo E, Galoppo MC, et al.Apoptosis mark-ers related to pathogenesis of pediatric chronic hepatitis C vi-rus infection:M30 mirrors the severity of steatosis[J].JMed Virol, 2010, 82 (6) :949-957.
|